Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production

Breast Cancer Research and Treatment

Volumn 149, Issue 1, 2015, Pages 49-57

  Bowers, Laura W ^a   Brenner, Andrew J ^b   Hursting, Stephen D ^a   Tekmal, Rajeshwar R ^c   deGraffenried, Linda A ^d  

^a IL   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d The University of Texas at Austin   (United States)

Author keywords

Aromatase; Cyclooxygenase 2; Interleukin 6; Obesity; Prostaglandin E2

Indexed keywords

AROMATASE; CELECOXIB; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 6; PROSTAGLANDIN E2; AROMATASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR;

ARTICLE; BODY MASS; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER PROGNOSIS; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MCF 7 CELL LINE; OBESITY; PARACRINE SIGNALING; POSTMENOPAUSE; PRIORITY JOURNAL; PROADIPOCYTE; PROSTAGLANDIN SYNTHESIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION; ADIPOCYTE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST TUMOR; COMPLICATION; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY;

ADIPOCYTES; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MCF-7 CELLS; OBESITY;

EID: 84925483228     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3223-0     Document Type: Article

References (36)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2013) SEER cancer statistics review, 1975–2010, National Cancer Institute. http://seer.cancer.gov/csr/1975_2010/. Accessed 2 Sept 2014
2. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330
3. Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307:491–497
4. Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123:627–635
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638
6. Chlebowski RT, Aiello E, McTiernan A (2002) Weight loss in breast cancer patient management. J Clin Oncol 20:1128–1143
7. Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW (1992) Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 116:26–32
8. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B (2008) Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 111:329–342
9. McTiernan A, Wu L, Chen C, Chlebowski R, Mossavar-Rahmani Y, Modugno F, Perri MG, Stanczyk FZ, Van Horn L, Wang CY (2006) Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity 14:1662–1677
10. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longcope C, Speizer FE (1995) Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87:1297–1302
11. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG (1989) The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 129:1120–1131
12. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28:3411–3415
13. Schmid P, Possinger K, Bohm R, Chaudri H, Verbeek A, Grosse Y, Luftner D, Petrides P, Sezer O, Wischnewsky M (2000) Body mass as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or megestrol acetate. Proc Annu Meet Am Soc Clin Oncol 2000:19
14. Folkerd EJ, Dixon JM, Renshaw L, A’Hern RP, Dowsett M (2012) Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 30:2977–2980
15. Suzuki T, Miki Y, Ohuchi N, Sasano H (2008) Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer 15:270–277
16. O’Neill JS, Elton RA, Miller WR (1988) Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J 296:741–743
17. Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE (2001) Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by C/EBPbeta. Cancer Res 61:2328–2334
18. Fain JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74:443–477
19. Maihofner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, Gooderham NJ (2003) Expression of cyclooxygenase-2 parallels expression of interleukin-1beta interleukin-6, and NK-kappaB in human colorectal cancer. Carcinogenesis 24:665–671
20. Falcone DJ, Sakamoto J, Steenport ML, Khan KM, Du B, Dannenberg AJ (2007) Interleukin 6 stimulates macrophage MMP-9 expression via COX-2 dependent induction of PGE2 synthesis and engagement of the EP4 receptor. FASEB J 21(383):3
21. Geng Y, Blanco FJ, Cornelisson M, Lotz M (1995) Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J Immunol 155:796–801
22. Bowers LW, Cavazos DA, Brenner AJ, Hursting SD, Maximo IX, Degraffenried LA (2013) Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression. Breast Cancer Res 15:R59
23. Ghosh S, Choudary A, Ghosh S, Musi N, Hu Y, Li R (2009) IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells. Mol Endocrinol 23:662–670
24. Bowers LW, Maximo IX, Brenner AJ, Beeram M, Hursting SD, Price RS, Tekmal RR, deGraffenried LA (2014) NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions. Cancer Res 74:4446–4457
25. Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB (1997) Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 21:355–359
26. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H (1995) Free insulin-like growth factor in human obesity. Metabolism 44:37–44
27. Wolters R, Schwentner L, Regierer A, Wischnewsky M, Kreienberg R, Wöckel A (2011) Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Treat 131:925–931
28. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM, Bulun SE (2001) Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. Cancer Res 61:2250–2255
29. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER (1981) Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 53:412–417
30. Price T, Aitken J, Head J, Mahendroo M, Means G, Simpson E (1992) Determination of aromatase cytochrome P450 messenger ribonucleic acid in human breast tissue by competitive polymerase chain reaction amplification. J Clin Endocrinol Metab 74:1247–1252
31. Deb S, Zhou J, Amin SA, Imir AG, Yilmaz MB, Lin Z, Bulun SE (2006) A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I. 3 and II by disrupting a transcriptional complex in breast adipose fibroblasts. J Biol Chem 281:2585–2597
32. Chen D, Reierstad S, Lin Z, Lu M, Brooks C, Li N, Innes J, Bulun SE (2007) Prostaglandin E(2) induces breast cancer related aromatase promoters via activation of p38 and c-Jun NH(2)-terminal kinase in adipose fibroblasts. Cancer Res 67:8914–8922
33. Chen D, Reierstad S, Fang F, Bulun SE (2011) JunD and JunB integrate prostaglandin E2 activation of breast cancer-associated proximal aromatase promoters. Mol Endocrinol 25:767–775
34. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, Du B, Brogi E, Crawford CB, Kopelovich L, Subbaramaiah K, Dannenberg AJ (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 4:1021–1029
35. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, Kopelovich L, Hudis CA, Dannenberg AJ (2012) Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2:356–365
36. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, Zhou XK, Blaho VA, Hla T, Yang P, Kopelovich L, Hudis CA, Dannenberg AJ (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 4:329–346